Coya Therapeutics, Inc.(COYA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Coya Therapeutics, Inc. (COYA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores COYA at 29.0/100 on a 32-signal composite quality model, placing it at rank #2,537 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Coya Therapeutics, Inc. reports quarterly revenue of $243.7K, net income of $-6.6M. Top institutional holders of COYA by reported 13-F value include DME Capital Management, VANGUARD CAPITAL MANAGEMENT, Alyeska Investment Group, L.P., based on the most recent SEC filings. COYA trades on the Nasdaq exchange and files with the SEC under CIK 1835022. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COYA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Coya Therapeutics, Inc. directly from SEC EDGAR.